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Abstract: The marine natural product, marinopyrrole A (1), was previously shown to have 
significant antibiotic activity against Gram-positive pathogens, including methicillin-resistant 
Staphylococcus aureus (MRSA). Although compound (1) exhibits a significant reduction 
in MRSA activity in the presence of human serum, we have identified key modifications 
that partially restore activity. We previously reported our discovery of a chloro-derivative 
of marinopyrrole A (1a) featuring a 2–4 fold improved minimum inhibitory concentration 
(MIC) against MRSA, significantly less susceptibility to serum inhibition and rapid and 
concentration-dependent killing of MRSA. Here, we report a novel fluoro-derivative of 
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marinopyrrole A (1e) showing an improved profile of potency, less susceptibility to serum 
inhibition, as well as rapid and concentration-dependent killing of MRSA. 
Keywords: antibiotics; non-symmetrical marinopyrroles; MRSA; SAR 
 
1. Introduction 
Since we reported the synthesis of novel non-symmetrical marinopyrrole derivatives retaining their 
potent activity against methicillin-resistant Staphylococcus aureus (MRSA), yet less susceptible to 
human serum inhibition [1], several research publications on the topic of marinopyrroles have 
appeared [2–7]. Biosynthesis of marinopyrrole A via an N,C-bipyrrole homocoupling catalyzed by two 
flavin-dependent halogenases was reported by the Moore group [2], and racemic marinopyrrole B by 
total synthesis and a review of the marinopyrroles were reported by the Clive group [3,4]. After 
optimization of the key step to avoid the formation of an oxazepine byproduct [5] that was reported in 
our first total synthesis of marinopyrroles [8], we published the most potent symmetrical 
marinopyrrole derivative against MRSA and methicillin-resistant Staphylococcus epidermidis  
(MRSE) [6]. Recently we reported a series of cyclic marinopyrroles as disruptors of Mcl-1 and Bcl-xL 
binding to Bim [7] and a series of novel marinopyrroles with potential as anticancer agents [9].  
The World Health Organization recognizes antibiotic resistance as a serious threat to human  
health [10]. The global crisis of antibiotic resistance has spread rapidly over the last several decades, 
with multidrug-resistant MRSA as a major cause of serious infections in the United States [11–15]. 
From 1999 to 2005, estimated MRSA hospitalizations in the U.S. more than doubled, increasing from 
127,000 to 280,000, and accounted for roughly 94,000 infections and close to 19,000 deaths in  
2005 [16]. That same year, more people in the U.S. died from MRSA infections than HIV/AIDS 
(16,000 people). MRSA infections cost U.S. hospitals between $3.2 and $4.2 billion annually [17]. 
Recent survey documents have shown that MRSA remains one of the most prevalent  
multidrug-resistant organisms causing healthcare-associated infections, and the MRSA prevalence in 
2010 is higher than that reported in 2006 [18]. The introduction of new MRSA antibiotics to clinical 
practice has been limited primarily to the oxazolidinone, linezolid [19], in 2000, the lipopeptide, 
daptomycin [20], in 2003, and ceftaroline [21]. Vancomycin remains the most commonly used first 
line treatment against MRSA. However, overreliance on this drug has resulted in an increase in MRSA 
with reduced susceptibility to vancomycin [22,23]. The minimum inhibitory concentration (MIC) shift 
(“the MIC creep”) for vancomycin has been especially noticeable in MRSA compared to other  
S. aureus [24]. In fact, vancomycin efficacy continues to decline, due to pathogen-developed  
resistance [22,24]. Instances of daptomycin [25] and linezolid [26,27] resistance have also surfaced. 
There are now several late-stage products in development, including tedizolid, dalbavancin, 
oritavancin and ceptobiprole. Although these antibiotics may add to the arsenal for combating MRSA 
resistance, bacteria inevitably develop resistance to all antibacterial agents that are introduced to the 
clinic [28]. Novel antibiotic agents of new structural classes and further advances in discovery research 
are urgently needed to overcome the problem of MRSA resistance. 
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The relative abandonment of the discovery and development of antibiotics by the pharmaceutical 
industry has opened opportunities for academic researchers to discover new antibiotics that treat these 
increasingly problematic infections. Here, we report our design and synthesis of novel marinopyrrole 
derivatives with excellent antibiotic activity against MRSA, but only limited serum inactivation. 
2. Results and Discussion 
2.1. Synthesis and Structural Activity Relationships of Non-Symmetrical Marinopyrrole Derivatives 
We classified marinopyrroles as “symmetrical” and “asymmetrical/non-symmetrical” in our 
previous publication to facilitate structure-activity relationship (SAR) discussions [1]. “Symmetrical” 
derivatives bear the same substituents and patterns on both phenyl Rings A and B attached to the 
carbonyl groups, while “non-symmetrical” marinopyrroles are those with different substituents for 
Rings A and B (Chart 1). As we envisaged that the “non-symmetrical” marinopyrrole derivatives 
should have different and possibly more favorable biological activity than their symmetrical 
counterparts, in particular, the molecules with diverse functional groups decorated on this unique  
1,3-bispyrrole system may adopt specific conformations, due to the restricted free rotation of the chiral 
axis. Indeed, a series of novel non-symmetrical marinopyrrole derivatives that we designed and 
synthesized showed potent anti-MRSA activity with a superior antibiotic profile to the parent 
marinopyrrole A (1) [1].  
Chart 1. Marinopyrroles. 
 
To continue our efforts of structure-activity relationship (SAR) optimization, we designed and 
synthesized a series of novel non-symmetrical marinopyrroles and evaluated their anti-MRSA activity. 
As shown in Chart 1 and Scheme 1, while Ring A was kept constant, substitutions with different 
halogen (F, Cl and Br) in the different position of Ring B were examined. Indeed, the effects of 
different halogen (F, Cl and Br) in Ring B on SARs, physicochemical properties and pH-dependent 
microspecies are observed, as detailed in Figures 1 and 2.  
Chemistries to access both symmetrical and non-symmetrical marinopyrrole derivatives have been 
reported [1,6,8,29]. Briefly, Friedel–Crafts arylation of mono acylated bispyrrole 2 [1,29] with the acid 
chlorides, 4, generated in situ from the corresponding carboxylic acids, 3, with thionyl chloride, 
afforded a series of marinopyrrole precursors, 5c–5f, in a 48%–71% yield. A novel series of  
non-symmetrical marinopyrrole derivatives, 6c–6f, were obtained in a 21%–60% yield by 
tetrachlorination of the corresponding 5c–5f using 4.1 equivalents of sulfuryl chloride (SO2Cl2) in 
DCM at 0 °C. Demethylation of 6c–6f using BBr3 in DCM at −78 °C furnished 1c–1f in a 31%–72% 
yield (Scheme 1). 
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Scheme 1. Synthesis of novel non-symmetrical marinopyrrole derivatives. 
 
Figure 1. Physicochemical properties and structure-activity relationship (SAR) of 
marinopyrrole derivatives against methicillin-resistant Staphylococcus aureus (MRSA). 
 
Compound MW f pKa 1 
a
 pKa 2 
a
 Clog p 
a
 THB 
c
 THB + 20% Serum 
c
 
1 (parent) 510.15 7.8 b 8.4 b 5.6 b 0.75 d 94–188 d 
1a 
d
 544.60 7.3 8.2 6.1 0.19–0.39 d 12.5–25 d 
1c 528.14 7.2 8.2 5.7 3.13 ND e 
1d 528.14 7.0 8.1 5.7 0.78 ND 
1e 528.14 7.6 8.3 5.7 0.19–0.78 25–50 
1f 589.05 7.5 8.2 6.4 1.56 ND 
Vanco g 1485.72    0.85–1.7 0.85–1.7 
a Calculated using ChemAxon Software Version 5.12.3 (ChemAxon, Budapest, Hungary); b reported in our 
previous paper [6]; c MIC, minimum inhibitory concentration in μM in Todd-Hewitt broth (THB) in the 
absence or presence of 20% human serum; all data were generated from experiments repeated four times;  
d results, except for the calculated pKa and log p-values, from our previous paper [1] for SAR discussions;  
e not determined; f MW, molecular weight; g Vanco, vancomycin. 
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Figure 2. pH-dependent microspecies of marinopyrroles. 
 
Microspecies 1 1a 1c 1d 1e 1f 
I 85.3/68.5/29.9 a 63.2/38.4/9.7 61.2/36.3/9.0 50.3/26.7/5.9 79.8/59.4/21.3 75.3/52.7/16.7 
II 7.1/14.3/24.8 29.2/44.4/45.0 31.2/46.5/45.7 42.0/56.1/48.8 6.6/12.4/17.6 17.1/30.0/38.0 
III 7.1/14.3/24.8 5.2/8.0/8.1 5.1/7.6/7.4 4.2/5.6/4.8 12.5/23.4/33.4 6.2/11.0/13.9 
IV 0.6/3.0/20.5 2.4/8.0/37.2 2.6/9.7/37.9 3.5/11.7/40.4 1.0/4.9/27.6 1.4/6.3/31.4 
V 0.0/0.0/0.01 0.0/0.0/0.01 0.0/0.0/0.01 0.0/0.0/0.01 0.0/0.0/0.02 0.0/0.0/0.01 
a Percentage (%) of microspecies distributions at pH 7.0/7.4/8.0, respectively, calculated using ChemAxon Software 
Version 5.12.3 (ChemAxon, Budapest, Hungary); numbers in italics are the percent of microspecies distributions at  
pH 7.0. 
The anti-MRSA activity of the novel non-symmetrical marinopyrroles was evaluated against a 
USA300 strain of community-associated MRSA using marinopyrrole A (1) as a control. The MIC values 
of 1a [(4-chloro-2-hydroxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-hydroxybenzoyl)-1′H-1,3′-bipyrrole-2-yl) 
methanone], which we reported previously [1], were used to facilitate the SAR discussions. Similar to 
the effects from chlorine substituted marinopyrroles [1], fluorine substitutions in Ring B have 
significant contributions to the antibacterial activity. Although non-symmetrical marinopyrrole with 
ortho-substitution of the carbonyl group (1c) is four times less potent than 1, those marinopyrroles 
with para-(1d) and meta-fluoro (1e) substitutions display similar or better activities than 1. One of the 
derivatives, (5-fluoro-2-hydroxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-hydroxybenzoyl)-1′H-1,3′-bipyrrol-2-yl) 
methanone (1e), exhibited potent antibacterial activity similar to that of 1a [1]. The 1–4 fold 
improvement in antibacterial activity from the parent compound, 1, was observed for this novel  
fluoro-substituted marinopyrrole derivative, 1e, as shown in Figure 1. Compound 1f with meta-bromo 
substitution also exhibited antibacterial activity, although the MIC value is two-fold less potent than 1. 
Most significantly, not only did Compound 1e show increased antibacterial activity compared to the 
parent compound, marinopyrrole A (1), but its activity was also less inhibited upon the addition of 
20% human serum (MIC 25–50 μM vs. 94–188 μM). In comparison to contemporary MRSA agents, 
Compound 1e is more potent than vancomycin against USA300 MRSA strain TCH1516 [30]. 
To understand the significant effects of the physicochemical properties on antibacterial activity, we 
calculated the pKa 1, pKa 2 and log p of all marinopyrrole derivatives (Figure 2). All fluoro-substituted 
marinopyrroles (1c–1e) have lower Clog p-values than 1, while their chloro-(1a) or bromo-(1f) 
counterparts are up to half a log unit higher. Although pKa 2 values do not vary much (8.1–8.4), the 
pKa 1 values change from 7.0 to 7.8, due to the substitution of halogen atoms in different positions of 
Ring B. Careful analysis of pKa data reveals that there are five microspecies, I–V, present, and their 
distributions depend on the pH, as shown in Figure 2. Although our MIC assays were performed at  
pH 7.0, microspecies distributions at pH 7.4 and 8.0 are also tabulated, as the latter conditions are 
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usually used for other assays [7,9]. At pH 7.0, 50%–85% of all marinopyrroles are in the form of 
Microspecies I, with the parent marinopyrrole, 1, being the most predominant (85%) Microspecies I 
(Figure 2); marinopyrroles 1 and 1e have similar distributions of Microspecies II, 7.1% and 6.6%, 
respectively; the rest are increasing from 17% (1f) to 42% (1d) Microspecies II; the variation of 
Microspecies III distributions is small from 4.2% (1d) to 12.5% (1e); both Microspecies IV and V are 
from 0.0% to 3.5% at pH 7 and may be considered negligible. Microspecies I–IV distributions of 
marinopyrroles vary significantly at pH 7.4 and 8.0 (Figure 2). Microspecies I is found in the free 
hydroxyl form for both phenol groups, which can serve as both hydrogen bond donors and acceptors. 
Microspecies II and III can provide one free hydroxyl and one phenoxide group, as shown in Figure 2. 
The former can provide both a hydrogen bond donor and acceptor in Ring A and only a hydrogen bond 
acceptor or phenoxide for ionic interactions in Ring B, and vice versa for the latter. Microspecies IV 
has both phenol groups in phenoxide form, which are only available as hydrogen bond acceptors or for 
ionic interactions. The microspecies and their distributions at different pH should have a significant 
impact on their antibacterial activity. 
Figure 3. In vitro time-kill analysis for marinopyrrole derivatives 1a (A) and 1e (B) 
against the USA300 community-associated MRSA strain TCH1516. MRSA was subjected 
to increasing concentrations of 1× (0.39 μM), 10× (3.9 μM) and 20× (7.8 μM) the MIC of 
the assayed derivatives or the vehicle control (none). Both derivatives showed potent 
concentration-dependent killing kinetics. At 20× (7.8 μM), Derivative 1e demonstrated 
more rapid bacterial killing at 3 h. 
 
2.2. In Vitro Time-Kill of Marinopyrrole Derivative 1e 
Our previous data showed that the marinopyrrole derivative, 1a, exhibited rapid killing kinetics, and 
we investigated whether 1e might also show similar kinetics compared to the parent molecule. 
Derivative 1e displayed strong concentration-dependent MRSA killing similar in profile to the parent 
compound [30]. The potency of Derivative 1e was especially evident at 20× the MIC (7.8 μM), 
yielding greater than a 4-log kill of MRSA at 4 h (Figure 3B). These killing kinetics parallel the effects 
previously seen with the natural product parent compound, (−)-1 [30]. Importantly, the tested 
concentration of 1e (MIC 0.39 μM) was half of the concentration of the parent natural product tested in 
time-kill analyses (MIC 0.75 μM or 0.375 μg/mL) [30]. Secondly at 3.9 μM (10× MIC), bacterial 
counts were reduced by nearly two log units at three hours incubation and on average by three log 
Mar. Drugs 2014, 12 2464 
 
 
units at six hours. In comparison, at six hours of incubation, the parent natural product only yielded a 
two log decrease in bacterial counts at concentrations two fold higher (7.5 μM) than that tested for 
Derivative 1e (3.9 μM) [30]. Furthermore, the actual tested compound concentration of (−)-1 was  
7.5 μM, two fold higher than that of Derivative 1e (3.9 μM) (Figure 3). In summary, we have 
discovered a second novel derivative of a natural product with favorable bactericidal activity against 
MRSA, even in the presence of human serum. These results provide additional data showing that the 
marinopyrrole A scaffold is amenable to modifications to increase its antibacterial activity.  
3. Experimental Section 
3.1. Synthesis of Compounds 5c–6f 
All chemicals and solvents were purchased from commercial suppliers and used without further 
purification. Preparative flash column chromatography was performed on silica gel 60, 0.040–0.063 mm 
(EMD Chemicals, Billerica, MA, USA). 
1
H NMR (400 MHz) spectra were recorded on a Varian 
AS400 with a 60-place automated sample changer (Thermo, Madison, WI, USA). High resolution  
ESI-MS spectra were recorded on an Agilent ESI-TOF LC-MS 6200 system (Agilent Technologies, 
Santa Clara, CA, USA). Preparative HPLC was performed on a Gilson HPLC system with UV 
detectors and a Gilson 215 liquid handler for auto injection and fraction collections (customized by HT 
Labs, San Diego, CA, USA). Analytical HPLC was performed on an Agilent 1100 series with diode 
array detectors and auto samplers (Agilent Technologies, Santa Clara, CA, USA). The specifications of 
HPLC analysis are as follows: flow rate, 1 mL/min; column, Intertsil, 2.5 μm, 4.6 × 150 mm; 
wavelength, 254 and 280 nm; mobile phase, A: H2O with 0.1% HCO2H, B: MeOH, gradient of 50%–95% 
B in 25 min. All tested compounds possessed a purity of not less than 95%. 
(2-(6-Fluoro-2-methoxybenzoyl)-1′H-1,3′-bipyrrol-2′-yl)(2-methoxyphenyl)methanone (5c). Into a 
solution of 6-fluoro-2-methoxybenzoic acid (116 mg, 0.67 mmol, 1.2 equivalent) in benzene (1.0 mL), 
SOCl2 (1.0 mL) was added at room temperature, and the resulting solution was refluxed for 2 h. The 
reaction mixture was concentrated under vacuum to generate 6-fluoro-2-methoxybenzoyl chloride 4a, 
which was used directly in the next step without purification. A solution of 4a in CH2Cl2 (DCM, 2 mL) 
was added to a slurry of AlCl3 (97 mg, 1.3 equivalent) in DCM (2.5 mL) at 0 °C, and then, a solution 
of 1′H-1,3′-bipyrrol-2′-yl(2-methoxyphenyl)methanone (2) [1] (150 mg, 0.56 mmol, 1.0 equivalent) in 
DCM (1.5 mL) was added dropwise. The resulting solution was allowed to warm to room temperature 
and stirred overnight. A saturated solution of NaHCO3 (10 mL) and DCM (10 mL) was then added, 
and the resulting mixture was stirred for 1 h and then filtered through Celite
®
 (Sigma-Aldrich, 
St. Louis, MO, USA). The mixture was extracted with DCM (3 × 10 mL). The organic layer was  
dried over anhydrous Na2SO4, and purified by flash column chromatography (silica gel, 
hexanes:DCM:EtOAc 4:4:1) to afford 168 mg of 5c as a white solid, 71% yield. 
1
H NMR (400 MHz, 
CDCl3) δ 9.79 (br s, 1H), 7.31–7.27 (m, 1H), 7.22–7.14 (m, 2H), 7.07 (t, J = 4.0 Hz, 1H), 6.75–6.68 (m, 
4H), 6.54–6.53 (m, 1H), 6.41–6.40 (m, 1H), 6.34 (t, J = 4.0 Hz, 1H), 5.70 (dd, J = 4.0, 2.6 Hz, 1H), 
3.80 (s, 3H), 3.76 (s, 3H). The same procedure as described above was followed to obtain 5d–5f. 
(2-(4-Fluoro-2-methoxybenzoyl)-1′H-1,3′-bipyrrol-2′-yl)(2-methoxyphenyl)methanone (5d). After 
flash column chromatography (silica gel, DCM:EtOAc 9:1), 113 mg of 5d was obtained as a yellowish 
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solid, 48% yield. 
1
H NMR (400 MHz, CDCl3) δ 9.71 (br s, 1H), 7.22–7.14 (m, 3H), 7.07–7.03  
(m, 1H), 6.71–6.60 (m, 5H), 6.32 (dd, J = 4.0, 1.7 Hz, 1H), 6.29 (t, J = 2.8 Hz, 1H), 5.83 (dd, J = 4.0,  
2.6 Hz, 1H), 3.77 (s, 3H), 3.70 (s, 3H). 
(2-(5-Fluoro-2-methoxybenzoyl)-1′H-1,3′-bipyrrol-2′-yl)(2-methoxyphenyl)methanone (5e). After 
flash column chromatography (silica gel, DCM:EtOAc 9:1), 118 mg of 5e was obtained as an  
off-white solid, 50% yield. 
1
H NMR (400 MHz, CDCl3) δ 9.45 (br s, 1H), 7.24–7.19 (m, 2H), 7.08–7.04 
(m, 2H), 6.89–6.86 (m, 2H), 6.73–6.68 (m, 3H), 6.35–6.32 (m, 2H), 5.85 (dd, J = 4.0, 2.6 Hz, 1H), 3.76 
(s, 3H), 3.70 (s, 3H). 
(2-(5-Bromo-2-methoxybenzoyl)-1′H-1,3′-bipyrrol-2′-yl)(2-methoxyphenyl)methanone (5f). After 
flash column chromatography (silica gel, DCM:EtOAc 9:1), 112 mg of 5f was obtained as a yellowish 
solid, 48% yield. 
1
H NMR (400 MHz, CDCl3) δ 9.71 (br s, 1H), 7.45 (dd, J = 8.8, 2.5 Hz, 1H),  
7.26–7.21 (m, 1H), 7.20–7.15 (m, 2H), 7.07 (t, J = 3.0 Hz, 1H), 6.80 (d, J = 8.8 Hz, 1H), 6.73  
(dt, J = 11.3, 8.4 Hz, 3H), 6.34–6.29 (m, 2H), 5.89 (dd, J = 4.0, 2.6 Hz, 1H), 3.75 (s, 3H), 3.69 (s, 3H). 
(6-Fluoro-2-methoxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-methoxybenzoyl)-1′H-[1,3′-bipyrrole]-2-yl) 
methanone (6c). To a solution of Compound 5c (150 mg, 0.36 mmol, 1 equivalent) in DCM (4 mL) at 
0 °C, SO2Cl2 (119 μL, 1.48 mmol, 4.1 equivalent) was added dropwise, and the solution was stirred at 
0 °C for 1 h. Saturated aqueous NaHCO3 solution (2 mL) was added, and the resulting mixture was 
extracted with DCM (3 × 4 mL). The combined organic layers were dried with anhydrous MgSO4, 
filtered and concentrated. The residue was purified by flash column chromatography (silica gel, 
DCM:hexane:EtOAc 1:1:0.1) to afford 6c (118 mg, 59% yield) as an off-white solid. 
1
H NMR  
(400 MHz, CDCl3) δ 10.48 (br s, 1H), 7.34 (td, J = 8.4, 6.7 Hz, 1H), 7.25–7.18 (m, 2H), 6.80  
(d, J = 8.4 Hz, 1H), 6.77–6.72 (m, 2H), 6.67 (t, J = 7.5 Hz, 1H), 6.37 (s, 1H), 3.80 (s, 3H),  
3.77 (s, 3H).  
(4-Fluoro-2-methoxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-methoxybenzoyl)-1′H-[1,3′-bipyrrole]-2-yl) 
methanone (6d). To a solution of compound 5d (125 mg, 0.30 mmol, 1 equivalent) in DCM (4 mL) at 
0 °C, SO2Cl2 (99 μL, 1.23 mmol, 4.1 equivalent) was added dropwise, and the solution was stirred at  
0 °C for 1 h. Saturated aqueous NaHCO3 solution (2 mL) was added, and the resulting mixture was 
extracted with DCM (3 × 4 mL). The combined organic layers were dried with anhydrous MgSO4, 
filtered and concentrated. The residue was purified by flash column chromatography (silica gel, 
DCM:hexane:EtOAc 1:1:0.1) to afford 6d (100 mg, 60% yield) as an off-white solid. 
1
H NMR  
(400 MHz, CDCl3) δ 10.60 (br s, 1H), 7.27–7.18 (m, 3H), 6.76 (d, J = 8.6 Hz, 1H), 6.67  
(ddd, J = 8.1, 6.2, 3.8 Hz, 3H), 6.32 (s, 1H), 3.80 (s, 3H), 3.72 (s, 3H). 
(5-Fluoro-2-methoxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-methoxybenzoyl)-1′H-[1,3′-bipyrrole]-2-yl) 
methanone (6e). To a solution of Compound 5e (270 mg, 0.64 mmol, 1 equivalent) in DCM (7 mL) at 
0 °C, SO2Cl2 (210 μL, 2.63 mmol, 4.1 equivalent) was added dropwise, and the solution was stirred at 
0 °C for 1 h. Saturated aqueous NaHCO3 solution (4 mL) was added, and the resulting mixture was 
extracted with DCM (3 × 4 mL). The combined organic layers were dried with anhydrous MgSO4, 
filtered and concentrated. The residue was purified by flash column chromatography (silica gel, 
DCM:hexane:EtOAc 4:4:0.5) to afford 6e (110 mg, 31% yield) as an off-white solid. 
1
H NMR  
(400 MHz, CDCl3) δ 9.81 (br s, 1H), 7.28 (dt, J = 2.7, 1.8 Hz, 1H), 7.17 (dd, J = 7.5, 1.7 Hz, 1H), 7.11 
(ddd, J = 9.1, 7.9, 3.1 Hz, 1H), 6.88 (ddd, J = 8.0, 6.8, 3.6 Hz, 2H), 6.79 (d, J = 8.3 Hz, 1H), 6.71  
(td, J = 7.5, 0.8 Hz, 1H), 6.34 (s, 1H), 3.78 (s, 3H), 3.74 (s, 3H). 
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(5-Bromo-2-methoxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-methoxybenzoyl)-1′H-[1,3′-bipyrrole]-2-yl) 
methanone (6f). To a solution of Compound 5f (110 mg, 0.23 mmol, 1 equivalent) in DCM (3 mL) at  
0 °C, SO2Cl2 (75 μL, 0.92 mmol, 4.1 equivalent) was added dropwise, and the solution was stirred at  
0 °C for 1 h. Saturated aqueous NaHCO3 solution (2 mL) was added, and the resulting mixture was 
extracted with DCM (3 × 4 mL). The combined organic layers were dried with anhydrous MgSO4, 
filtered and concentrated. The residue was purified by flash column chromatography (silica gel, 
DCM:hexane:EtOAc 4:4:0.5) to afford 6f (30 mg, 21% yield) as an off-white solid. 
1
H NMR  
(400 MHz, CDCl3) δ 10.53 (br s, 1H), 7.50 (dd, J = 8.8, 2.5 Hz, 1H), 7.32–7.27 (m, 1H), 7.20  
(dd, J = 8.6, 2.1 Hz, 2H), 6.81 (dd, J = 14.3, 8.6 Hz, 2H), 6.74 (td, J = 7.5, 0.7 Hz, 1H), 6.33 (s, 1H), 
3.77 (s, 3H), 3.72 (s, 3H).  
3.2. Synthesis of Compounds 1c–1f 
(6-Fluoro-2-hydroxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-hydroxybenzoyl)-1′H-1,3′-bipyrrol-2-yl) 
methanone (1c). To a solution of 6c (118 mg, 0.21 mmol) in anhydrous DCM (2 mL) was slowly 
added 1.0 M solution of BBr3 in DCM (848 μL, 0.84 mmol, 4 equivalent) via a syringe under N2  
at −78 °C. After being stirred for 0.5 h, the mixture was quenched by the addition of MeOH (0.5 mL) 
and then H2O (3 mL) and extracted with DCM (3 × 10 mL). The combined organic layers were dried 
over anhydrous MgSO4, filtered and concentrated in vacuum. The residue was purified by column 
chromatography (silica gel, hexanes:EtOAc 10:1) to give 1c (40 mg, 36% yield) as a yellow solid.  
1
H NMR (400 MHz, CDCl3) δ 10.47 (s, 1H), 10.01 (s, 1H), 9.80 (br s, 1H), 7.43–7.36 (m, 2H),  
7.35–7.29 (m, 1H), 6.93 (d, J = 8.3 Hz, 1H), 6.82 (d, J = 8.5 Hz, 1H), 6.79 (d, J = 5.2 Hz, 1H),  
6.68–6.62 (m, 1H), 6.49 (t, J = 7.6 Hz, 1H). HRMS (ESI-TOF) [M + H]+ calcd. for C22H12Cl4FN2O4 
526.9530, found 526.9521; HPLC purity, 95.1%. 
(4-Fluoro-2-hydroxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-hydroxybenzoyl)-1′H-1,3′-bipyrrol-2-yl) 
methanone (1d). To a solution of 6d (100 mg, 0.18 mmol) in anhydrous DCM (2 mL) was slowly 
added a 1.0 M solution of BBr3 in DCM (720 μL, 0.72 mmol, 4 equivalent) via a syringe under N2  
at –78 °C. After being stirred for 0.5 h, the mixture was quenched by the addition of MeOH (0.5 mL) 
and then H2O (4 mL) and extracted with DCM (3 × 10 mL). The combined organic layers were dried 
over anhydrous MgSO4, filtered and concentrated in vacuum. The residue was purified by column 
chromatography (silica gel, hexanes:EtOAc 10:1) to give 1d (29 mg, 31% yield) as a yellow solid. 
1
H 
NMR (400 MHz, CDCl3) δ 11.60 (s, 1H), 10.41 (s, 1H), 9.84 (br s, 1H), 7.57 (dd, J = 8.9, 6.5 Hz, 1H), 
7.45 (dd, J = 8.0, 1.6 Hz, 1H), 7.39–7.34 (m, 1H), 6.93 (d, J = 8.4 Hz, 1H), 6.71 (s, J = 10.3, 2.5 Hz, 
1H), 6.67 (d, J = 1.7 Hz, 1H), 6.65–6.58 (m, 1H), 6.56–6.50 (m, 1H). HRMS (ESI-TOF) [M + H]+ 
calcd. for C22H12Cl4FN2O4 526.9530, found 526.9533; HPLC purity, 95.2%. 
(5-Fluoro-2-hydroxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-hydroxybenzoyl)-1′H-1,3′-bipyrrol-2-yl) 
methanone (1e). To a solution of 6e (160 mg, 0.29 mmol) in anhydrous DCM (4 mL) was slowly 
added a 1.0 M solution of BBr3 in DCM (1160 μL, 1.16 mmol, 4 equivalent) via a syringe under N2  
at –78 °C. After being stirred for 0.5 h, the mixture was quenched by the addition of MeOH (0.5 mL) 
and then H2O (5 mL) and extracted with DCM (3 × 10 mL). The combined organic layers were dried 
over anhydrous MgSO4, filtered and concentrated in vacuum. The residue was purified by column 
chromatography (silica gel, hexanes:EtOAc 10:1) to give 1e (110 mg, 72% yield) as a yellow solid.
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1
H NMR (400 MHz, CDCl3) δ 10.91 (s, 1H), 10.36 (s, 1H), 9.71 (br s, 1H), 7.41–7.36 (m, 2H),  
7.27–7.22 (m, 1H), 7.14 (dd, J = 8.8, 3.0 Hz, 1H), 6.99 (dd, J = 9.1, 4.5 Hz, 1H), 6.94 (d, J = 8.4 Hz, 
1H), 6.72 (s, 1H), 6.54 (t, J = 7.6 Hz, 1H). HRMS (ESI-TOF) [M + H]
+
 calcd. for C22H12Cl4FN2O4 
526.9530, found 526.9531; HPLC purity, 98.4%. 
(5-Bromo-2-hydroxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-hydroxybenzoyl)-1′H-1,3′-bipyrrol-2-yl) 
methanone (1f). To a solution of 6f (30 mg, 0.05 mmol) in anhydrous DCM (2 mL) was slowly added 
a 1.0 M solution of BBr3 in DCM (196 μL, 0.196 mmol, 4 equivalent) via a syringe under N2 at –78 °C. 
After being stirred for 0.5 h, the mixture was quenched by addition of MeOH (0.5 mL) and then H2O 
(2 mL) and extracted with DCM (3 × 5 mL). The combined organic layers were dried over anhydrous 
MgSO4, filtered and concentrated in vacuum. The residue was purified by column chromatography 
(silica gel, hexanes:EtOAc 10:1) to give 1f (12 mg, 42% yield) as a yellow solid. 
1
H NMR (400 MHz, 
CDCl3) δ 
1
H NMR (400 MHz, CDCl3) δ 11.12 (s, 1H), 10.35 (s, 1H), 9.82 (s, 1H), 8.10–8.04 (m, 2H), 
7.83 (d, J = 8.2 Hz, 1H), 7.67 (t, J = 7.7 Hz, 1H), 7.58 (dd, J = 8.8, 2.3 Hz, 1H), 7.44 (t, J = 7.6 Hz, 
1H), 6.92 (d, J = 8.9 Hz, 1H), 6.86 (s, 1H). HRMS (ESI-TOF) [M + H]
+
 calcd. for C22H12BrCl4N2O4 
586.8729, found 586.8731; HPLC purity, 95.6%. 
3.3. In Vitro Antibacterial Assays 
TCH1516, a USA300 strain of community-associated MRSA, was obtained from the American 
Type Culture Collection (Manassas, VA, USA) and used for biological assays. MICs were determined 
by broth microdilution in 96-well tissue-culture treated plates (Falcon Becton Dickson, Franklin Lakes, 
NJ, USA) according to Clinical and Laboratory Standards Institute guidelines, except that Todd-Hewitt 
broth (THB) was used in place of Mueller-Hinton broth. Vancomycin (NOVAPLUS Hospira, Inc. 
Lake Forest, IL, USA) served as a control antibiotic. MIC assays in 20% human serum were assessed 
by bacterial metabolic activity in resazurin, as described [30]. 
3.4. In Vitro Time-Kill Analysis 
The bactericidal activity of Derivative 1e against the MRSA isolate TCH1516 was assessed by 
time-kill analysis, as described previously [30–33]. Briefly, MRSA was grown overnight in  
Todd-Hewitt broth (THB) at 37 °C with shaking. Following overnight growth, MRSA was inoculated 
in fresh media for growth to the mid-logarithmic phase. At the start of the time-kill assay, bacteria 
(starting inoculum ~5 × 10
5
 colony forming units (CFU/mL)) were added to duplicate 5-mL polystyrene  
round-bottom tubes (Falcon, Bedford, MA, USA) containing 20×, 10× or 1× of the MIC of  
Derivative 1e (0.39 μM) or an equivalent amount of dimethyl sulfoxide (DMSO, Sigma-Aldrich,  
St. Louis, MO, USA) vehicle control (Figure 3, none). These cultures were incubated in a shaking  
37 °C incubator for 24 h. To determine the rate of antibiotic killing, small aliquots were removed from 
tubes at 0, 3, 6 and 24 h and serially diluted for CFU enumeration on Todd-Hewitt agar plates  
(Hardy Diagnostics, Santa Maria, CA, USA). The limit of detection for the time-kill assay was  
1.6 (log10 CFU/mL). 
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4. Conclusions 
In our continuation of studies of novel non-symmetrical derivatives of the marine natural product, 
marinopyrrole A, we identified a derivative, designated as 1e, with favorable bactericidal activity 
against MRSA (MIC = 0.19–0.78 μM). Furthermore, our time-kill studies indicate potent  
concentration-dependent killing with 1e that is at least comparable or slightly better than the parent 
natural product in parallel studies. One of the main drawbacks of the natural product has been its 
significant reduction in anti-MRSA activity (a 128 to 256 fold increase in MIC) in the presence of 
human serum. Importantly, 1e is clearly less serum-inhibited with only a 32–64 fold increase in MIC 
in 20% human serum (Figure 3). Future derivatization and SAR optimization will continue to identify 
more potent analogs with activity in human serum. 
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